Cancer Immunotherapy Drug Simultaneously Targets Two Proteins that Block Immune Response

Two independent groups of researchers have fused a TGF-beta receptor to a monoclonal antibody that targets a checkpoint protein. The result is a single hybrid molecule called a Y-trap that blocks two pathways used by tumors to evade the immune system.

https://ift.tt/2GBd7C5